Deals
Market Rebounds in November; OIS Index Does Not
The OIS Index of ophthalmic stocks declined by 2.3% in November on the heels of a 17.7% decline in October, failing to participate in the market rebound that lifted most stocks following the October sell-off. During November, the overall US stock market as measured by the Russell 3000 Index gained 1.8% following its 7.5% decline…
Read MoreOIS@AAO Has a Record Year; So Does Ophthalmology Sector
CHICAGO – A record crowd gathered for the 10th anniversary of OIS@AAO last week in Chicago, and one of the highlights is always the Year in Review delivered by OIS chairman Emmett Cunningham Jr., MD, PhD, MPH, who summarized “a banner year – a remarkable year really” for ophthalmology approvals by the Food and Drug…
Read MoreOIS Index Follows Stock Market Lower in October
The OIS Index of ophthalmic stocks declined by 17.7% during the October market correction, which saw a 7.5% decline in the overall US stock market as measured by the Russell 3000 Index. Healthcare stocks underperformed in October: the NASDAQ Biotechnology Index lost 14.6% of its value, and a composite of US medical device stocks declined…
Read MoreThe Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards
The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD Dr. Ahmed has been a leader in novel treatments for glaucoma, cataract, and lens implant surgery. His pioneering work in innovative glaucoma surgery includes coining the term microinvasive glaucoma surgery…
Read MoreThe Gems You’ll Find at OIS@AAO 2018
Diamonds are emerging as the new 10th anniversary gift. Here’s a look at a few of gems you can mine at the 10th OIS@AAO in two Thursdays, on October 25, at the Marriott Marquis in Chicago a day before the American Academy of Ophthalmology (AAO) annual meeting gets underway. Breakfast Breakout Sessions. This year’s seven…
Read MoreSmall Cap Stocks Lead the Way for OIS Index in September
The OIS Index of ophthalmic stocks gave back some of its recent gains in September, declining by 4.1% against an overall flat market backdrop. The NASDAQ Biotechnology Index and the overall US stock market as measured by the Russell 3000 Index were essentially unchanged during the month, while a composite of US medical device stocks…
Read MoreGlaukos and STAAR Drive OIS Index into Record Territory
The OIS Index of ophthalmic stocks surged to new highs in August, driven by two of the highest-weighted stocks in the index. The OIS Index gained 16.3% in August, while the overall US stock market, as measured by the Russell 3000 Index gained 3.3%, the NASDAQ Biotechnology Index gained 4.8%, and a composite of US…
Read MoreOIS Index Lags Market Benchmarks in July
The OIS Index of ophthalmic stocks declined by 1.1% in July, against a strong overall market backdrop. During the month, the overall US stock market as measured by the Russell 3000 Index gained 3.9%, while the NASDAQ Biotechnology Index gained 8.6% and a composite of US medical device stocks gained 4.7%. Within the index, declining…
Read MoreOIS Index Hits New Highs; Two New Companies Added
The OIS Index stayed in four-digit territory in June, finishing the month at 1,017 and again outperforming its stock market benchmarks. The OIS Index gained 2.1% during the month, while the NASDAQ Biotechnology Index declined by 0.9%; the overall US stock market, as measured by the Russell 3000 Index, declined by 0.1%; and a composite…
Read MoreWhat’s Next for Alcon Spin-off
As Novartis unveiled plans to spin off its Alcon eye care unit, the Swiss healthcare giant named Alcon CEO Mike Ball chairman-designate to guide the transformation of the Fort Worth, TX-based unit into a Swiss-based global device company. How much will the spin-off bring in? In the announcement, Novartis also said it would buy back…
Read MoreOIS Index Breaks 1,000 as Rally in Ophthalmic Stocks Rolls On
The OIS Index returned to four-digit territory in May, surpassing 1,000 for the first time since the index was launched in October 2016. The OIS Index was initially set to 1,000 on October 1, 2016, and over the ensuing 20 months, US stocks have gained 30% in value and other developed markets have gained more…
Read MoreOphthalmic Stocks’ Rally Rolls Through April
The OIS Index gained 5.2% in April, on the heels of a 4.4% gain in March. Ophthalmic stocks have far outperformed key market benchmarks over the past one and three months. The NASDAQ Biotechnology Index declined 3% in April, while the overall US stock market as measured by the Russell 3000 Index gained 0.3% and…
Read More